PharmaEngine
4162.TWO
2.71 USD
-0.02
-0.73%
p
Overview
Last close
2.71 usd
Market cap
384.05M usd
52 week high
3.68 usd
52 week low
2.32 usd
Target price
4.13 usd
Valuation
P/E
6.4175
Forward P/E
N/A
Price/Sales
4.3957
Price/Book Value
2.0342
Enterprise Value
190.23M usd
EV/Revenue
2.1725
EV/EBITDA
2.5171
Key financials
Revenue TTM
87.56M usd
Gross Profit TTM
85.87M usd
EBITDA TTM
71.40M usd
Earnings per Share
0.42 usd
Dividend
0.21 usd
Total assets
179.19M usd
Net debt
N/A usd
About
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
- Symbol4162.TWO
- ExchangeTWO
- IsinTW0004162003
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Hong-Ren Wang Ph.D.
- HeadquarterTaipei
- Web sitehttps://www.pharmaengine.com
